T1	p 30 39	high risk
T2	p 90 123	for metastatic breast cancer with
T3	p 401 449	patients with metastatic breast cancer ( MBC ) .
T4	p 630 639	MBC ( n =
T5	p 777 796	ie , > or =grade II
T6	p 865 875	documented
T7	p 886 887	.
T8	p 1254 1270	poor performance
T9	p 1421 1426	age .
T10	p 1443 1448	score
T11	p 1454 1467	> or =25 to <
T12	p 1593 1601	Patients
T13	p 1607 1608	a
T14	p 1863 1881	those MBC patients
T15	i 124 172	doxorubicin or pegylated liposomal doxorubicin :
T16	i 305 306	)
T17	i 314 396	chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD )
T18	i 524 527	DOX
T19	i 540 541	2
T20	i 552 568	weeks ) or PLD (
T21	i 579 580	2
T22	i 765 776	) cells/L (
T23	i 787 798	=grade II )
T24	i 1138 1145	scoring
T25	i 1325 1334	) cells/L
T26	i 1378 1407	chemotherapy , DOX versus PLD
T27	i 1770 1859	by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD )
T28	i 1918 1952	anthracycline-based chemotherapy .
T29	o 44 55	neutropenic
T30	o 286 299	complications
T31	o 720 745	absolute neutrophil count
T32	o 823 845	febrile neutropenia or
T33	o 1259 1305	performance status , absolute neutrophil count
T34	o 1429 1448	precycle risk score
T35	o 1541 1552	sensitivity
T36	o 1568 1579	specificity
T37	o 1844 1850	factor